Methotrexate in paediatric and adolescent Crohn’s disease: an observational study

Brief summary (registry, in English)

[PK] Determination of MTX-PG concentrations and identification of accumulation patterns over time in RBCs. [PD] Association of MTX-PG concentration with MTX discontinuation due to a lack of efficacy or toxicity.

What you commit to

• Study type: Interventional · Phase 4
• Planned participants: 215
• 4 sites in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children, teenagers and young adults with Crohn's disease who are about to start methotrexate (MTX), alone or together with infliximab.

Age

4-28 years

Sex

Women and men can join.

Disease stage

Crohn's disease proven by endoscopic, radiological and histologic findings.

Earlier treatment

Must be about to start MTX treatment, either alone or together with infliximab. Cannot be treated with a biologic agent other than infliximab.

Main reasons for not taking part

• Not able to receive MTX, as in usual care
• Treatment with a biologic agent other than infliximab
• Cannot read and understand the patient and family information sheets
• Informed consent of the patient not obtained when required

Read by machine on 9 Nov 2026.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: - to 64 years · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (4)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details